Dark

VRTX
Vertex Pharmaceuticals Inc
stock NASDAQ

At Close

May 8, 2025 3:59:59 PM EDT

429.67USD-1.184%(-5.15)2,940,973

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 8, 2025 8:57:30 AM EDT

431.00USD-0.879%(-3.82)1,342

After-hours

May 8, 2025 4:00:30 PM EDT

429.60USD+0.012%(+0.05)22,636

OverviewOptionsHistoricalExchangesShortsNews

Jan 28, 2022

11:27AM EST Hearing Vertex Pharmaceuticals Joins IBD Leaderboard Benzinga

Jan 27, 2022

06:54AM EST Vertex Pharmaceuticals Clocks 27% Growth In Product Revenues, Issues FY22 Guidance Benzinga

Jan 26, 2022

04:56PM EST Vertex Pharma Q4 EPS $3.00 Vs. $2.30 Last Year RTTNews

04:24PM EST Recap: Vertex Pharmaceuticals Q4 Earnings Benzinga

04:22PM EST Vertex Pharmaceuticals Inc. (VRTX) revealed a profit for its fourth quarter that increased from last year and beat the Street estimates. RTTNews

04:06PM EST Vertex Sees FY22 Product Revenue $8.4B-$8.6B Benzinga

04:04PM EST Vertex Pharmaceuticals Q4 EPS $3.37 Beats $3.29 Estimate, Sales $2.07B Beat $2.00B Estimate Benzinga

04:01PM EST Vertex Reports Fourth Quarter 2021 and Full Year Financial Results Business Wire

08:29AM EST The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data Benzinga

03:59AM EST Earnings Scheduled For January 26, 2022 Benzinga

Jan 23, 2022

11:03AM EST The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More Benzinga

Jan 21, 2022

05:16AM EST Where Vertex Pharmaceuticals Stands With Analysts Benzinga

Jan 20, 2022

10:41AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2022 Benzinga

07:28AM EST 10 Biggest Price Target Changes For Thursday Benzinga

04:50AM EST BMO Capital Upgrades Vertex Pharmaceuticals to Outperform, Raises Price Target to $274 Benzinga

Jan 19, 2022

08:06AM EST SiteOne Therapeutics Announces Collaboration And License Agreement With Vertex Pharmaceuticals To Advance NaV1.7 Inhibitors For Treatment Of Pain Benzinga

Jan 18, 2022

04:05PM EST Vertex to Announce Fourth Quarter 2021 Financial Results on January 26 Business Wire

Jan 11, 2022

04:08AM EST Vertex Pharmaceuticals Inc. (VRTX) said Tuesday that the European Commission or EC has granted approval for the label extension of Kaftrio in a combination regimen with Ivacaftor, for the treatment of cystic fibrosis or CF in children with gene mutations. RTTNews

03:07AM EST Vertex Pharma: EU Approves KAFTRIO In Combination With Ivacaftor For Cystic Fibrosis In Patients Ages 6 Through 11 Years RTTNews

03:01AM EST European Commission Approves KAFTRIO(r) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years Business Wire

Jan 4, 2022

04:05PM EST Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10 Business Wire

10:06AM EST Vertex Shares Quiet On Light Volume; Traders Circulate Dealreporter Alert Highlighting Previously-Announced Co. Deal With Moderna Benzinga

Dec 29, 2021

09:55AM EST $100 Invested In This Stock 10 Years Ago, Would Be Worth This Much Benzinga

Dec 9, 2021

09:50PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 Benzinga

09:47PM EST Wells Fargo Initiates Coverage On Vertex Pharmaceuticals with Overweight Rating, Announces Price Target of $270 Benzinga

08:41AM EST Direxion Launches mRNA ETF (MSGR) PR Newswire

Dec 2, 2021

11:10AM EST What 6 Analyst Ratings Have To Say About Vertex Pharmaceuticals Benzinga

07:28AM EST RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $265 Benzinga

Dec 1, 2021

08:43AM EST Vertex Pharmaceuticals Incorporated (VRTX) said, in a phase 2 proof-of-concept study in patients with APOL1-mediated focal segmental glomerulosclerosis, VX-147 on top of standard of care achieved a statistically significant, substantial and clinically meaningful mean reduction of 47.6% in the urine protein to creatinine ratio at week 13 compared to baseline. RTTNews

07:38AM EST Vertex Announces Positive Results From Phase 2 Study Of VX-147 In APOL1-Mediated FSGS RTTNews

07:38AM EST Vertex Announces Results From Phase 2 Study Of VX-147 In APOL1-Mediated Focal Segmental Glomerulosclerosis; Says 'Treatment with VX-147 led to a statistically significant, substantial and clinically meaningful mean reduction in proteinuria of 47.6%' Benzinga

07:36AM EST State News' Adam FeuersteinIn Tweets: ;a medical first, Vertex $VRTX drug successfully targets the underlying cause of a genetic kidney disease' Benzinga

07:35AM EST State News Adam FeuersteinIn Tweets: ;a medical first, Vertex $VRTX drug successfully targets the underlying cause of a genetic kidney disease' Benzinga

07:30AM EST Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis Business Wire

Nov 19, 2021

12:01PM EST Expert Ratings For Vertex Pharmaceuticals Benzinga

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

06:39AM EST Vertex Pharma: Spanish Government Approves Terms For RTTNews

06:03AM EST Vertex Announces Reimbursement Deal In Spain For KAFTRIO In Combination With Ivacaftor To Treat Cystic Fibrosis RTTNews

06:02AM EST Vertex Pharma Reports Reimbursement Deal In Spain For KAFTRIO In Combo With Ivacaftor To Treat People With Cystic Fibrosis 12 Years+ With At Least 1 F508del Mutation Benzinga

06:00AM EST Vertex Announces Reimbursement Agreement in Spain for KAFTRIO(r) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene Business Wire

05:29AM EST BMO Capital Initiates Coverage On Vertex Pharmaceuticals with Market Perform Rating, Announces Price Target of $202 Benzinga

04:53AM EST Piper Sandler Downgrades Vertex Pharmaceuticals to Neutral, Lowers Price Target to $218 Benzinga

Nov 17, 2021

12:55PM EST Watching Vertex Pharmaceuticals; Evercore Issues Note, Sets $245 Price Target Benzinga

Nov 12, 2021

07:39AM EST Vertex Pharmaceuticals Incorporated (VRTX) said the European Medicines Agency's CHMP adopted a positive opinion for the label extension of KAFTRIO in a combination regimen with ivacaftor, for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene. RTTNews

07:33AM EST Vertex Receives CHMP Positive Opinion For KAFTRIO In Combination With Ivacaftor In Children With Cystic Fibrosis Ages 6 Through 11 Benzinga

07:30AM EST Vertex Gets CHMP Positive Opinion For KAFTRIO In Combination With Ivacaftor In Children With Cystic Fibrosis RTTNews

07:27AM EST Vertex Receives CHMP Positive Opinion for KAFTRIO(r) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11 Business Wire

Nov 3, 2021

09:21AM EDT RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $250 Benzinga

Nov 2, 2021

05:34PM EDT Recap: Vertex Pharmaceuticals Q3 Earnings Benzinga

04:36PM EDT Vertex Pharmaceuticals Sees FY21 Sales Guidance From $7.2B-$7.4B To $7.4B-$7.5B Vs. $7.32B Est. Benzinga

04:33PM EDT Vertex Pharmaceuticals Q3 EPS $3.56 Beats $3.08 Estimate, Sales $1.98B Beat $1.86B Estimate Benzinga

04:12PM EDT Vertex Pharma Q3 EPS $3.28 Vs. $2.53 Year Ago RTTNews

04:08PM EDT Vertex Pharmaceuticals Inc. (VRTX) revealed a profit for its third quarter that climbed from last year. RTTNews

04:01PM EDT Vertex Reports Third-Quarter 2021 Financial Results Business Wire

10:54AM EDT The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 27, 2021

12:08PM EDT Vertex Reports Its Supplement To New Drug Application For TRIKAFTA In Patients Ages 6-11 Accepted By Health Canada For Priority Review Benzinga

12:08PM EDT (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada PR Newswire

Oct 26, 2021

01:47PM EDT Jennifer Doudna Spinout Mammoth Inks $700M CRISPR Deal With Vertex Benzinga

09:14AM EDT Vertex Pharmaceuticals, Mammoth Biosciences Announce Collaboration To Develop In Vivo Gene-Editing Therapies For Series Diseases Benzinga

Oct 22, 2021

08:00AM EDT Vertex to Announce Third-Quarter 2021 Financial Results on November 2 Business Wire

Oct 19, 2021

08:12AM EDT Vertex Pharma Reports 5 Scientific Abstracts About Co.'s Cystic Fibrosis Portfolio Will Be Presented At North American Cystic Fibrosis Conference Nov. 2-5, 2021 Benzinga

08:07AM EDT Vertex To Present Long-Term Data Demonstrating Significant Benefits Of Treatment With CFTR Modulators RTTNews

08:00AM EDT Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC) Business Wire

Oct 18, 2021

05:46PM EDT Vertex Unveils First Patient Results On Potential Diabetes Treatment Benzinga

08:03AM EDT Vertex Pharmaceuticals Inc. (VRTX) announced positive day 90 data for the first patient in the phase 1/2 clinical trial dosed With VX-880, a novel investigational stem cell-derived therapy for the treatment of Type 1 Diabetes. RTTNews

07:35AM EDT Vertex Announces Positive Day 90 Data In Phase 1/2 Trial Of VX-880 For Type 1 Diabetes RTTNews

07:33AM EDT Vertex Announces Day 90 Data For First Patient In Phase 1/2 Clinical Trial Dosed With VX-880; Demonstrated Restoration Of Insulin Production, Showed 91% Decrease In Daily Insulin Requirement And 'robust improvements in glucose control' Benzinga

07:30AM EDT Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes Business Wire

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

Sep 28, 2021

08:18AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive Benzinga

08:16AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments Benzinga

Sep 23, 2021

07:57AM EDT The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data Benzinga

Sep 22, 2021

11:18AM EDT Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada Benzinga

11:17AM EDT Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada PR Newswire

Sep 21, 2021

04:34PM EDT Vertex Energy Receives Request For Additional Information From The U.S. Federal Trade Commission Regarding Its Pending Asset Divestiture To Safety-Kleen Systems, Inc. Benzinga

Sep 17, 2021

04:20PM EDT Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(r)(elexacaftor/tezacaftor/ivacaftor and ivacaftor) PR Newswire

Sep 13, 2021

08:00AM EDT Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th Business Wire

Sep 10, 2021

07:51AM EDT Cramer Gives His Opinion On Service Corporation, Vertex And More Benzinga

Sep 9, 2021

01:19PM EDT Expert Ratings For Vertex Pharmaceuticals Benzinga

11:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 Benzinga

06:57AM EDT Stifel Downgrades Vertex Pharmaceuticals to Hold, Lowers Price Target to $213 Benzinga

Sep 7, 2021

01:46PM EDT Where Vertex Pharmaceuticals Stands With Analysts Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021 Benzinga

06:14AM EDT Morgan Stanley Downgrades Vertex Pharmaceuticals to Underweight, Announces $202 Price Target Benzinga

Aug 26, 2021

05:56PM EDT Where Vertex Pharmaceuticals Stands With Analysts Benzinga

07:11AM EDT Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA in People With Cystic Fibrosis Benzinga

07:06AM EDT Vertex Publishes Phase 3 Results For TRIKAFTA In Cystic Fibrosis In The New England Journal Of Medicine RTTNews

07:00AM EDT Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA(r) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis Business Wire

Aug 25, 2021

03:41PM EDT First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age PR Newswire

03:41PM EDT Health Canada Grants Marketing Authorization for KALYDECO (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age Benzinga

Aug 24, 2021

09:02AM EDT Vertex Inks Potential $1.2B Gene-Editing Pact With Arbor Biotechnologies Benzinga

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

07:12AM EDT Vertex and Arbor Biotechnologies Establish New Partnership To Develop Novel ex vivo Engineered Cell Therapies; Arbor To Receive Upfront Payment And Up To $1.2B In Milestones Benzinga

07:00AM EDT Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Arbor Biotechnologies (Arbor) today announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbors proprietary CRISPR gene-editing technology for select diseases. GlobeNewswire Inc

Aug 17, 2021

01:50PM EDT Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma Benzinga

Aug 10, 2021

02:42PM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

Aug 7, 2021

11:36AM EDT Last Week's Notable Insider Buys: Magnolia Oil & Gas, Vertex Pharmaceuticals Benzinga

11:35AM EDT Last Week's Notable Insider Buys: Magnolia Oil & Gas, Vertex Pharmaceuticals And More Benzinga

Aug 4, 2021

09:18AM EDT Vertex Earlier Announced Appointment Of Stuart A. Arbuckle As Chief Operating Officer Benzinga

08:34AM EDT Vertex Appoints Stuart Arbuckle As COO RTTNews

08:30AM EDT Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer Business Wire

Jul 30, 2021

12:34PM EDT Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Lowers Price Target to $202 Benzinga

12:14PM EDT Expert Ratings for Vertex Pharmaceuticals Benzinga

10:53AM EDT Piper Sandler Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $323 Benzinga

10:35AM EDT RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $248 Benzinga

07:13AM EDT SVB Leerink Maintains Underperform on Vertex Pharmaceuticals, Raises Price Target to $175 Benzinga

Jul 29, 2021

06:02PM EDT Vertex Pharmaceuticals Inc. (VRTX) lifts its full year 2021 revenue outlook. The company now expects revenues of $7.2 billion to $7.4 billion for the full year 2021. RTTNews

04:48PM EDT Vertex Pharmaceuticals: Q2 Earnings Insights Benzinga

04:17PM EDT Vertex Pharma Q2 EPS $0.26 Vs. $3.18 Year Ago RTTNews

04:13PM EDT Vertex Pharmaceuticals Inc. (VRTX) announced a profit for second quarter that fell from the same period last year. RTTNews

04:12PM EDT Vertex Pharmaceuticals Raises FY21 Sales Guidance From $6.7B-$6.9B To $7.2B-$7.4B Vs. $6.99B Est. Benzinga

04:12PM EDT Vertex Pharmaceuticals Inc. (VRTX) released a profit for second quarter that fell from the same period last year. RTTNews

04:11PM EDT Vertex Pharmaceuticals Q2 EPS $3.11 Beats $2.28 Estimate, Sales $1.79B Beat $1.72B Estimate Benzinga

04:02PM EDT Vertex Reports Second-Quarter 2021 Financial Results Business Wire

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 28, 2021

08:49AM EDT Vertex Pharmaceuticals Inc. (VRTX) said that it will initiate a phase 3 development program for the new once-daily investigational triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor) in people with Cystic Fibrosis. The Phase 3 program is expected to begin in the second half of 2021. RTTNews

08:05AM EDT Vertex To Initiate Phase 3 Development Program For Once-Daily Triple Combination Regimen In People With Cystic Fibrosis RTTNews

08:04AM EDT Vertex Reports Phase 2 Study Of Once-Daily Triple Combo Regimen For People With Cystic Fibrosis Met Primary Endpoint; Co. Plans To Initiation Phase 3 Trial In H2'21 Benzinga

08:00AM EDT Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis Business Wire

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 21, 2021

11:49AM EDT Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next? Benzinga

Jul 20, 2021

11:42AM EDT Where Vertex Pharmaceuticals Stands With Analysts Benzinga

11:41AM EDT UPDATE: SVB Leerink On Vertex Pharmaceuticals Downgrade: Firm Sees Biopharma Multiple Compression Occurring With Expectations Of >$10B To Supplement Internal Research Efforts & Portfolio; Projects FY1 Multiple Down Another 25% Over Coming Year Benzinga

10:14AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021 Benzinga

07:48AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:19AM EDT SVB Leerink Downgrades Vertex Pharmaceuticals to Underperform, Lowers Price Target to $170 Benzinga

Jul 19, 2021

08:05AM EDT Vertex Initiates Phase 2 Clinical Trial Program For VX-548 For Treatment Of Acute Pain Benzinga

Jul 16, 2021

04:01PM EDT Vertex to Announce Second-Quarter 2021 Financial Results on July 29 Business Wire

Jul 7, 2021

08:04AM EDT Eloxx Pharma Sees Data Readout From First Four Arms Of Cystic Fibrosis Study By End Of 2021 Benzinga

Jul 1, 2021

02:29PM EDT Expert Ratings For Vertex Pharmaceuticals Benzinga

10:11AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021 Benzinga

09:56AM EDT UPDATE: Raymond James On Vertex Market Perform Initiation: Firm Believes The Current Set-Up For Co. Is Unfavorable And Believes Shares Will Be Pressured Over Next 6 Months Given Competitive Risk, Although Co. Expected To Drive Value In Long-Term Benzinga

05:00AM EDT Raymond James Initiates Coverage On Vertex Pharmaceuticals with Market Perform Rating Benzinga

Jun 30, 2021

08:43AM EDT Vertex Announces Vertex Tax Links Integration For Mirakl Benzinga

Jun 28, 2021

09:36AM EDT Vertex Announces National Reimbursement Agreement In France For KAFTRIO And SYMKEVI For Eligible Cystic Fibrosis Patients Benzinga

09:32AM EDT Vertex Announces National Reimbursement Deal In France For KAFTRIO And SYMKEVI For Eligible Cystic Fibrosis Patients RTTNews

09:27AM EDT Vertex Announces National Reimbursement Agreement in France for KAFTRIO(r) (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI(r) (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients Business Wire

Jun 25, 2021

01:45PM EDT Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO, SYMKEVI and Additional Indications of ORKAMBI and KALYDECO for Eligible Patients With Cystic Fibrosis Benzinga

01:44PM EDT Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO(r), SYMKEVI(r) and Additional Indications of ORKAMBI(r) and KALYDECO(r) for Eligible Patients With Cystic Fibrosis Business Wire

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

Jun 18, 2021

03:51PM EDT (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation PR Newswire

03:38PM EDT Vertex Reports Health Canada Granted Marketing Authorization For TRIKAFTA In People 12+ With At Least 1 F508del Mutation Benzinga

03:37PM EDT Health Canada Grants Marketing Authorization for TRIKAFTA(r) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation Business Wire

07:46AM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

Jun 17, 2021

09:49AM EDT Cramer Gives His Opinion On Bank of America, Advanced Micro Devices And More Benzinga

08:33AM EDT The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme Benzinga

Jun 16, 2021

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

08:02AM EDT Cramer Shares His Thoughts On Vertex Pharma, Snap And More Benzinga

Jun 15, 2021

08:07AM EDT The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda Benzinga

Jun 14, 2021

10:21AM EDT Piper Sandler Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $261 Benzinga

09:45AM EDT Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $331 Benzinga

09:32AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:35AM EDT SVB Leerink Maintains Market Perform on Vertex Pharmaceuticals, Lowers Price Target to $200 Benzinga

Jun 11, 2021

11:18AM EDT What 11 Analyst Ratings Have To Say About Vertex Pharmaceuticals Benzinga

10:33AM EDT Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials Benzinga

10:03AM EDT Shares of Vertex Pharmaceuticals Incorporated (VRTX) are down more than 8% Friday morning. RTTNews

08:55AM EDT Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Lowers Price Target to $205 Benzinga

08:49AM EDT Citigroup Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $285 Benzinga

08:43AM EDT Baird Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $240 Benzinga

08:29AM EDT Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $307 Benzinga

08:26AM EDT Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $281 Benzinga

08:20AM EDT Stifel Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $244 Benzinga

08:05AM EDT The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts Benzinga

07:48AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:02AM EDT RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $242 Benzinga

06:49AM EDT Barclays Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $285 Benzinga

06:23AM EDT Despite Hitting Mid-Stage Trial Endpoint Goal, Vertex Strikes Out Rare Lung Disease Candidate; Stock Tumbles Benzinga

03:12AM EDT Vertex, CRISPR Announce New Data On 22 Patients Treated With Investigational CRISPR/Cas9-based Gene-editing Therapy RTTNews

03:05AM EDT Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001(tm) at European Hematology Association Annual Meeting Business Wire

Jun 10, 2021

04:08PM EDT Vertex Says Co 'will not advance VX-864 into late-stage development and instead will advance additional novel small' Benzinga

04:03PM EDT Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency Business Wire

04:03PM EDT Vertex Pharmaceutical Shares Move Lower; Stat News Reports 'Vertex shelves second drug for inherited lung disease, raising concerns about future growth' Benzinga

Jun 9, 2021

11:13AM EDT Vertex Pharmaceuticals Issues Correction To Previous Press Release Correcting Dosages For TRIKAFTA Tablets Benzinga

11:04AM EDT CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA(r) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations Business Wire

08:46AM EDT Vertex Pharma's Trikafta Triplet Therapy Wins FDA Approval For Expanded Use In Children 6-11 Years With Cystic Fibrosis Benzinga

08:37AM EDT FDA Oks Vertex's Trikafta In Children With CF Ages 6 RTTNews

08:08AM EDT Vertex: FDA Approves TRIKAFTA In Children With Cystic Fibrosis Ages 6 Thro 11 With Certain Mutations RTTNews

08:04AM EDT Vertex Announces FDA Approval For TRIKAFTA In Children With Cystic Fibrosis Ages 6 Through 11 With Certain Mutations Benzinga

08:00AM EDT Vertex Announces U.S. FDA Approval for TRIKAFTA(r) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations Business Wire

Jun 8, 2021

09:17AM EDT The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex Benzinga

Jun 2, 2021

10:38AM EDT Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Benzinga

May 18, 2021

06:43AM EDT Concert Pharma Sells VX-561-Related Milestones To Vertex For $32M Benzinga

May 17, 2021

04:08PM EDT Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32M Benzinga

May 12, 2021

11:03AM EDT Vertex, CRISPR Therapeutics To Present New Clinical Data On Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies At Annual European Hematology Association Virtual Congress Benzinga

11:00AM EDT Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for presentation during the European Hematology Association (EHA) 2021 Virtual Congress. GlobeNewswire Inc

May 10, 2021

09:01AM EDT Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13 Business Wire

Apr 30, 2021

09:14AM EDT Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $254 Benzinga

Apr 29, 2021

04:48PM EDT Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its first quarter that increased from the same period last year. RTTNews

04:17PM EDT Vertex Pharmaceuticals: Q1 Earnings Insights Benzinga

04:14PM EDT Vertex Pharma Q1 EPS $2.49 Vs. $2.29 Year Ago RTTNews

04:01PM EDT Vertex Reports First-Quarter 2021 Financial Results Business Wire

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 26, 2021

08:34AM EDT Vertex, CRISPR Report Priority Medicines Designation Granted By European Medicines Agency For Its Transfusion-Dependent Beta Thalassemia Candidate Benzinga

08:30AM EDT Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) GlobeNewswire Inc

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 22, 2021

09:06AM EDT Vertex Pharma Inks Research, Licensing Agreement With Obsidian Therapeutics For Controllable Genetic Therapies Benzinga

08:25AM EDT Vertex Pharma, Obsidian Announce Research Collaboration RTTNews

08:08AM EDT Vertex, Obsidian Therapeutics Collaborate To Discover Novel Therapies That Regulate Gene Editing RTTNews

08:08AM EDT Vertex Says Establishes Collaboration With Obsidian Therapeutics To 'Discover Novel Therapies That Regulate Gene Editing' Benzinga

08:00AM EDT Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing Business Wire

Apr 20, 2021

07:20AM EDT Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia Benzinga

07:15AM EDT - Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- GlobeNewswire Inc

Apr 19, 2021

11:25AM EDT Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $253 Benzinga

09:01AM EDT Vertex to Announce First-Quarter 2021 Financial Results on April 29 Business Wire

Apr 8, 2021

04:31PM EDT Markets Set New All-Time Closing Highs. Here's Why. Benzinga

Apr 2, 2021

07:46AM EDT The Nasdaq Soared Today. Here's Why. Benzinga

Mar 26, 2021

07:23AM EDT Vertex Reports Positive CHMP Opinion For KAFTRIO In Combo With Ivacaftor To Treat People With Cystic Fibrosis With At Least One F508del Mutation Benzinga

Mar 25, 2021

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 24, 2021

07:21PM EDT Vertex Receives Australian TGA Approval for TRIKAFTA(r) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation Business Wire

Mar 10, 2021

08:08AM EST Vertex Pharmaceuticals Incorporated (VRTX) announced the FDA has granted Fast Track Designation for VX-880. VX-880, formerly known as STx-02, is an investigational allogeneic human stem cell-derived islet cell therapy that is being evaluated for patients who have type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. RTTNews

08:01AM EST Vertex Says FDA Has Granted Fast Track Designation For VX-880 RTTNews

07:57AM EST Vertex Announces FDA Fast Track Designation And Initiation Of Phase 1/2 Clinical Trial For VX-880 In Type 1 Diabetes Benzinga

07:55AM EST Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes Business Wire

Feb 24, 2021

09:01AM EST Vertex to Present at the Cowen Health Care Conference on March 2 Business Wire

06:42AM EST Cramer Weighs In On Canopy Growth, Dish Network And More Benzinga

Feb 23, 2021

11:08AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2021 Benzinga

07:41AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

05:58AM EST Baird Upgrades Vertex Pharmaceuticals to Outperform, Raises Price Target to $252 Benzinga

Feb 3, 2021

08:45AM EST An Aging Population is Increasing the Need for Novel Treatments PR Newswire

Feb 2, 2021

12:09PM EST Piper Sandler Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $347 Benzinga

11:52AM EST BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $284 Benzinga

08:51AM EST Credit Suisse Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $280 Benzinga

08:22AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

08:05AM EST The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga

06:35AM EST SVB Leerink Maintains Market Perform on Vertex Pharmaceuticals, Lowers Price Target to $250 Benzinga

06:00AM EST A Peek Into The Markets: US Stock Futures Gain; Alphabet, Amazon.com Earnings In Focus Benzinga

Feb 1, 2021

05:08PM EST Vertex Pharmaceuticals Q4 GAAP EPS $2.30, Adj. EPS $2.51 Misses $2.59 Estimate, Sales $1.63B Beat $1.58B Estimate Benzinga

05:08PM EST CORRECTION: Vertex Q4 Adj. EPS $2.51Misses $2.59 Estimate Benzinga

04:39PM EST Vertex Pharmaceuticals: Q4 Earnings Insights Benzinga

04:12PM EST Vertex Pharmaceuticals Inc. (VRTX) reported a profit for its fourth quarter that advanced from the same period last year. RTTNews

04:06PM EST Vertex Pharma Q4 EPS $2.30 Vs. $2.23 Year Ago RTTNews

04:02PM EST Vertex Pharmaceuticals Q4 Adj. EPS $2.30 Misses $2.59 Estimate, Sales $1.63B Beat $1.58B Estimate Benzinga

04:01PM EST Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results Business Wire

04:00AM EST Earnings Scheduled For February 1, 2021 Benzinga

Jan 30, 2021

01:19PM EST The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More Benzinga

Jan 29, 2021

10:12AM EST Earnings Preview for Vertex Pharmaceuticals Benzinga

07:45AM EST The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga

Jan 28, 2021

04:15PM EST Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-880 For Treatment Of Type 1 Diabetes RTTNews

04:11PM EST Vertex Reports FDA Clearance Of Investigational New Drug Application For VX-880 For Treatment Of Type-1 Diabetes Benzinga

04:11PM EST Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D) Business Wire

Jan 26, 2021

08:45AM EST Vertex Pharma Reports FDA Accepted Supplemental New Drug Aplpication For TRIKAFTA In Children With Cystic Fibrosis Ages 6-11 With Certain Mutations Benzinga

Jan 22, 2021

09:08AM EST Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1 Business Wire

Jan 19, 2021

10:09AM EST Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $251 Benzinga